Other

Biogen Idec, Inc.

Idec Pharmaceuticals Corporation

Rougier Inc.

William S Shestowsky

Nabil Hanna

Peter Brams

Darrell R Anderson

Cheryl Janne Heard

Hanna Sikorska

The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three PRIMATIZED&#xae; antibodies derived from those monkey monoclonal antibodies which bind B7.1 and possibly B7.2, PRIMATIZED&#xae; 7C10, PRIMATIZED&#xae; 7B6 and PRIMATIZED&#xae; 16C10. These PRIMATIZED&#xae; and monkey antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

Anti-CD80 antibodies

The present invention relates to methods for treating B cell lymphoma using CD80-specific antibodies.

Methods for treating b cell lymphoma using CD80-specific antibodies

The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three primatized antibodies derived from those monkey monoclonal antibodies which bind B7.1 and possibly B7.2, primatized 7C10, primatized 7B6 and primatized 16C10. These primatized and monkey antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

Treatment of psoriasis using anti-B7.1 (CD80) antibodies

Human B7.1-specific primatized antibodies and transfectomas expressing

The present invention relates to an anti-idiotypic monoclonal antibody raised against a mouse monoclonal antibody or fragments thereof specific to at least one diarrhetic shellfish poisoning toxin selected from the group consisting of okadaic acid and derivatives thereof. The anti-idiotypic antibody is characterized by reacting only with antibodies to okadaic acid and derivatives thereof but not with antibodies directed against any other compounds. The anti-idiotypic antibody is further characterized by being an internal image of okadaic acid and derivatives thereof. A hybridoma producing an anti-idiotypic antibody in accordance with the present invention has been deposited at the ATCC under accession number HB 10768. Competitive solid-phase assays for determining the amount of okadaic acid and derivatives thereof in marine samples are also provided in accordance with the present invention. The present invention also relates to a kit for determining the amount of okadaic acid and derivatives thereof in marine samples.

Growing community of inventors

San Diego, CA, United States of America

William S Shestowsky